Cargando…
Identification of Plasma Proteins as Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease Using Liquid Chromatography–Tandem Mass Spectrometry
Blood proteins can be used for biomarkers to monitor the progression of cognitive decline, even in the early stages of disease. In this study, we developed a liquid chromatography–tandem mass spectrometry (LC-MS/MS)-based blood test to identify plasma proteins that can be used to detect mild cogniti...
Autores principales: | Inoue, Makoto, Suzuki, Hideaki, Meno, Kohji, Liu, Shan, Korenaga, Tatsumi, Uchida, Kazuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488247/ https://www.ncbi.nlm.nih.gov/pubmed/37685872 http://dx.doi.org/10.3390/ijms241713064 |
Ejemplares similares
-
Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment
por: Liu, Shan, et al.
Publicado: (2019) -
Determination of Mebudipine in Human Plasma by Liquid Chromatography–tandem Mass Spectrometry
por: Asgari, Arezoo, et al.
Publicado: (2015) -
Establishment to measure oxycodone in plasma with liquid chromatography–tandem mass spectrometry
por: Ito, Suguru, et al.
Publicado: (2022) -
Determination of thalidomide concentration in human plasma by liquid chromatography-tandem mass spectrometry
por: BAI, NAN, et al.
Publicado: (2013) -
Quantification of Human Plasma-Busulfan Concentration by Liquid Chromatography-Tandem Mass Spectrometry
por: Moon, Soo Young, et al.
Publicado: (2014)